Insilico Screening Of Novel Pyrimidinones As Potential Her2 Inhibitors Targeting Breast Cancer

The molecular docking and ADME screening of newer 4-[4-(dimethylamino)phenyl]-6-phenylpyrimidin-2(5H)-ones derivatives were carried out. One of the major subtypes of breast cancer has overexpression of HER2. So here, all the compounds are screened for HER2 inhibitor activity. The ADME studies are performed on the SWISSADME webserver. The docking studies are performed in Autodock Vina integrated PyRx. Results depict that all derivatives binding affinity is greater than standard trastuzumab at the active site of HER2 and have significant ADME properties.